[Open study on the effect and side effects of @entity7689 , used at the 2d and 3d therapeutic step in essential XXXX ].

@entity1 @entity10 @entity7689 @entity101
An open study was undertaken to investigate the efficacy and adverse effects of @entity7689 in 33 @entity1 with essential @entity101 whose blood pressure was uncontrolled (diastolic blood pressure 96 to 115 mm Hg) despite previous treatment with one or two antihypertensive drugs. @entity7689 was added to the existing antihypertensive therapy and the dose titrated to a maximum of 150 mg/day or until blood pressure control was achieved (diastolic blood pressure less than 90 mm Hg or a reduction in diastolic blood pressure of 15 mm Hg). @entity1 were then followed up for a further 4 weeks. @entity7689 significantly reduced mean standing systolic and diastolic blood pressure from 167/113 +/- 19.8/7.2 (SD) mm Hg to 150.3/101.1 +/- 23.4/8.9 (SD) mm Hg after 10 weeks and mean supine systolic and diastolic blood pressure from 169.8/110.8 +/- 16.4/5.6 (SD) mm Hg to 154.2/102.1 +/- 23.8/12 (SD) mm Hg after 10 weeks. Blood pressure was controlled in 21 of the 33 @entity1 (63.6%) studied. @entity7689 caused a small but significant fall in pulse rate of 3.9 beats per minute, in the supine position, after 4 weeks therapy. 10 @entity1 experienced adverse effects, the most common being dizziness and @entity10 (3 @entity1 each), and lightheadedness/fainting on standing (2 @entity1 ). No @entity1 experienced sedation. Only 1 @entity1 was withdrawn from the trial because of adverse effects (fainting on standing). Biochemical and haematological investigations carried out pretreatment and during treatment showed no abnormalities related to @entity7689 treatment.
